Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6ZSG1
UPID:
ARK2C_HUMAN
Alternative names:
RING finger protein 165
Alternative UPACC:
Q6ZSG1; B3KVD1
Background:
E3 ubiquitin-protein ligase ARK2C, also known as RING finger protein 165, plays a pivotal role in motor axon elongation. It enhances the transcriptional responses of SMAD1/SMAD5/SMAD8 effectors, crucial for motor axon extension in the dorsal forelimb. ARK2C achieves this by mediating the ubiquitination and subsequent degradation of SMAD inhibitors like SMAD6, SMAD7, SKI, and SNON isoform of SKIL.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase ARK2C could open doors to potential therapeutic strategies.